Expert review of respiratory medicine最新文献_第10页

Recent advances in the diagnosis and management of pulmonary alveolar proteinosis. 肺泡蛋白沉积症的诊断与治疗进展。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-08-08 DOI: 10.1080/17476348.2025.2538274

Elisabeth Bendstrup, Evelyn Lynn, Marissa O'Callaghan

{"title":"Recent advances in the diagnosis and management of pulmonary alveolar proteinosis.","authors":"Elisabeth Bendstrup, Evelyn Lynn, Marissa O'Callaghan","doi":"10.1080/17476348.2025.2538274","DOIUrl":"10.1080/17476348.2025.2538274","url":null,"abstract":"Introduction: Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by the accumulation of surfactant-derived material in the alveolar spaces due to impaired macrophage function. Autoimmune PAP (aPAP) is caused by neutralizing autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) and accounts for over 90% of cases. PAP causes respiratory symptoms and, in severe cases, respiratory failure necessitating lung transplantation. Early diagnosis and intervention are crucial. This narrative review is based on a PubMed literature search last performed 30 March 2025.Areas covered: This review examines the pathophysiology, diagnosis, and treatment of PAP. We focus on GM-CSF autoantibody testing and bronchoalveolar lavage (BAL) for diagnosis and treatment modalities including whole lung lavage (WLL) and inhaled GM-CSF therapy. The use of rituximab, plasmapheresis, and lung transplantation for refractory cases is also discussed.Expert opinion: The advent of WLL and GM-CSF has advanced the care of patients with aPAP. However, challenges still remain in managing treatment-resistant cases, and for patients with non-autoimmune forms of PAP where treatment options are more limited. Further research is needed to optimize therapeutic strategies, especially for patients who do not respond to first-line treatments. Timely diagnosis and early intervention remain essential for improving patient outcomes.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1247-1261"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The use of biologic therapies in pediatric severe asthma. 儿童重症哮喘生物治疗的应用。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-08-05 DOI: 10.1080/17476348.2025.2535182

Cristiana Indolfi, Angela Klain, Michele Miraglia Del Giudice, Maria De Filippo, Alessia Marseglia, Gian Luigi Marseglia, Amelia Licari

{"title":"The use of biologic therapies in pediatric severe asthma.","authors":"Cristiana Indolfi, Angela Klain, Michele Miraglia Del Giudice, Maria De Filippo, Alessia Marseglia, Gian Luigi Marseglia, Amelia Licari","doi":"10.1080/17476348.2025.2535182","DOIUrl":"10.1080/17476348.2025.2535182","url":null,"abstract":"Introduction: Severe asthma in children is a chronic, heterogeneous condition that significantly impacts quality of life and poses management challenges. The introduction of biological therapies has transformed treatment paradigms, offering targeted interventions for patients with specific phenotypes.Areas covered: This review provides an overview of the current evidence on biologic therapies approved for pediatric severe asthma, including omalizumab, mepolizumab, benralizumab, and dupilumab. We discuss their mechanisms of action, pivotal clinical trials, real-world data, and practical considerations for use. A comprehensive literature search was performed using PubMed, Embase, and major conference proceedings up to May 2025. We also examine emerging biologic agents targeting upstream pathways, such as tezepelumab and anti-IL-33 therapies, and explore the concept of asthma remission and its implications for long-term disease trajectories.Expert opinion: Biologics represent a significant advancement in pediatric asthma management, enabling for tailored treatments based on underlying pathophysiology. However, challenges persist in optimizing patient selection, enhancing access, and comprehending long-term outcomes. Future research should focus on early intervention strategies, cost-effectiveness analyses, and the potential for disease-modifying effects in children.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1209-1219"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of COPD exacerbations in hospital emergency departments. 医院急诊科慢性阻塞性肺病加重的管理。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-07-12 DOI: 10.1080/17476348.2025.2530207

Pascual Piñera Salmerón, Esther Pulido Herrero, Raúl Perales Muñoz, Arturo Huerta García, Raúl Alonso Avilés, Cesar Cinesi Gómez, Juan González Del Castillo

{"title":"Management of COPD exacerbations in hospital emergency departments.","authors":"Pascual Piñera Salmerón, Esther Pulido Herrero, Raúl Perales Muñoz, Arturo Huerta García, Raúl Alonso Avilés, Cesar Cinesi Gómez, Juan González Del Castillo","doi":"10.1080/17476348.2025.2530207","DOIUrl":"10.1080/17476348.2025.2530207","url":null,"abstract":"Introduction: Emergency departments (EDs) play a crucial role in managing exacerbation of COPD (ECOPD). However, there is currently no standardization of management criteria for ECOPD within the Spanish healthcare system. This document aims to outline the management of ECOPD in EDs in the context of 2025, serving as a guide for healthcare professionals working in emergency services.Areas covered: Various aspects of the management of ECOPD in EDs are covered in this article, including severity classification, treatments (both pharmacological and nonpharmacological), criteria for hospital admission and discharge from the ED, treatment at discharge, palliative care, and management of frail patients.Expert opinion: The authors, who are members of the Spanish Society of Emergency Medicine (SEMES), emphasize the importance of classifying the severity of the episode and the patient characteristics to tailor care to each individual. The authors also highlight the value of biomarkers, the appropriate use of ventilatory therapies for ECOPD patients, the importance of proper antibiotic management, and the establishment of clear referral protocols to prevent patients from feeling lost in the healthcare system. Finally, the need to personalize post-discharge treatments is underscored to enhance continuity of care and improve health outcomes.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1181-1191"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of obesity on COPD development: unveiling the hidden risks. 肥胖对慢性阻塞性肺病发展的影响：揭示潜在风险。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-07-06 DOI: 10.1080/17476348.2025.2528945

Ioannis Tomos, Nikolaos Skourlis, Georgia Vourli, Eleni Peppa, Antonia Trichopoulou

{"title":"The impact of obesity on COPD development: unveiling the hidden risks.","authors":"Ioannis Tomos, Nikolaos Skourlis, Georgia Vourli, Eleni Peppa, Antonia Trichopoulou","doi":"10.1080/17476348.2025.2528945","DOIUrl":"10.1080/17476348.2025.2528945","url":null,"abstract":"Background: Obesity represents a frequent comorbidity in chronic obstructive pulmonary disease (COPD); however, its exact role as potential risk factor remains unclear. ur aim is to assess obesity's potential role for COPD development.Research design and methods: The HYDRIA survey has been the first national project on the health of the population in Greece. Data regarding individual characteristics, lifestyle choices, medical history, dietary data and somatometric characteristics were recorded through personal interview in a representative sample of the population.Results: Four thousand eleven men and women aged more than 18 years old were enrolled. COPD is more prevalent in obese people (10.1%; 95% CI: 6.0-14.2%) compared to 5.4%; 95% CI: 4.6-6.2% in non-obese participants. In multivariate analysis, obesity continues to be strongly associated with COPD (OR = 1.76 (95% CI: 1.23-2.53); p = 0.002). Age and smoking are also strong risk factors for COPD. The estimated prevalence of self-reported physician-diagnosed COPD in Greece is 5.9%.Conclusions: Obesity may represent a potential unrevealed risk factor for COPD. Focus on obesity should be included in public health campaigns and preventive programs aiming to decrease the burden of disease and provide the necessary optimal management.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1297-1303"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vitamin D deficiency and severity of non-cystic fibrosis bronchiectasis: a systematic review. 维生素D缺乏与非囊性纤维化支气管扩张的严重程度：一项系统综述。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-07-20 DOI: 10.1080/17476348.2025.2535764

Dafni Moriki, Despoina Koumpagioti, Michalis Kalogiannis, Maria Tsouprou, Konstantinos Douros

{"title":"Vitamin D deficiency and severity of non-cystic fibrosis bronchiectasis: a systematic review.","authors":"Dafni Moriki, Despoina Koumpagioti, Michalis Kalogiannis, Maria Tsouprou, Konstantinos Douros","doi":"10.1080/17476348.2025.2535764","DOIUrl":"10.1080/17476348.2025.2535764","url":null,"abstract":"Introduction: Vitamin D deficiency is common in cystic fibrosis (CF) and may be linked to disease severity. We aimed to investigate the association between vitamin D deficiency and severity in non-CF bronchiectasis.Methods: A systematic search of PubMed and Scopus (up to December 2024) identified relevant studies. After screening 170 articles, seven met the inclusion criteria. Study quality was assessed using NIH tools.Results: Patients with non-CF bronchiectasis had significantly lower serum 25-hydroxyvitamin D (25OHD) levels compared to healthy controls. In one study, median 25OHD was 24.7 nmol/L in patients vs. 45.3 nmol/L in controls. Another reported mean levels of 14.7 ± 9.6 ng/mL vs. 19.8 ± 6.9 ng/mL, respectively. Disease severity was assessed using validated and semi-structured measures, including the bronchiectasis severity index (BSI), number of exacerbations, pulmonary function tests (PFTs), radiological scores (Bhalla, modified Reiff), and health-related quality-of-life (HRQL) tools. Most studies reported worse severity outcomes in vitamin D-deficient patients.Conclusions: Although vitamin D deficiency appears to be associated with more severe non-CF bronchiectasis, heterogeneity between studies limits definitive conclusions. Future studies should incorporate standardized tools such as the eFACED score to better characterize disease severity.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1263-1272"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. 索他塞普治疗肺动脉高压的疗效和安全性：随机对照试验的荟萃分析。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-07-06 DOI: 10.1080/17476348.2025.2530201

Mohamad Ershed, Ana Beatriz Nardelli da Silva, Ana Clara Felix de Farias Dos Santos, Danhui Heo, Deivyd Vieira Silva Cavalcante, Jafar Aljazeeri

{"title":"Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials.","authors":"Mohamad Ershed, Ana Beatriz Nardelli da Silva, Ana Clara Felix de Farias Dos Santos, Danhui Heo, Deivyd Vieira Silva Cavalcante, Jafar Aljazeeri","doi":"10.1080/17476348.2025.2530201","DOIUrl":"10.1080/17476348.2025.2530201","url":null,"abstract":"Introduction: To evaluate the efficacy and safety of sotatercept, an activin signaling inhibitor, in pulmonary arterial hypertension (PAH).Methods: We searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) comparing sotatercept versus placebo in PAH. We calculated pooled risk ratios (RR) and mean differences (MD) with their 95% confidence intervals (CI) using a random-effects model. Heterogeneity was assessed with I2 statistics. The GRADE approach was used to assess the certainty of evidence.Results: Three RCTs comprising 601 patients were included. Compared to placebo, sotatercept significantly improved 6-minute walk distance (MD 40.57 m; 95% CI 26.64 to 54.5; p < 0.01), and WHO functional class (RR 2.04; 95% CI 1.53 to 2.7; p < 0.01). Sotatercept reduced pulmonary vascular resistance (MD -233.18 dyn·sec·cm-5; 95% CI -295.84 to -170.52; p < 0.01) and pulmonary artery pressure (MD -14.94 mmHg; 95% CI -19.62 to -10.27; p < 0.01) at study end. No significant differences were observed in all-cause mortality or NT-proBNP levels. Sotatercept was associated with epistaxis, increased hemoglobin, and telangiectasia adverse events.Conclusions: Sotatercept improves exercise capacity, WHO functional class and pulmonary hemodynamics in PAH, with an acceptable safety profile. Long-term studies are needed to confirm sustained benefits.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251032174.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1273-1281"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhaled argon for cardiopulmonary resuscitation: current knowledge and future clinical potential. 吸入氩气用于心肺复苏：目前的知识和未来的临床潜力。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-07-03 DOI: 10.1080/17476348.2025.2528944

Matthias L Riess, Claudius Balzer, Zhu Li, Matthew B Barajas

引用次数: 0

An updated guide for clinicians: extracorporeal membrane oxygenation for pediatric patients with refractory acute respiratory failure. 临床医生更新指南：难治性急性呼吸衰竭患儿体外膜氧合。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-07-24 DOI: 10.1080/17476348.2025.2536887

Makenzie Hamilton, Marybeth Burriss-West, Desiree Bonadonna, Caroline P Ozment, Kyle J Rehder

{"title":"An updated guide for clinicians: extracorporeal membrane oxygenation for pediatric patients with refractory acute respiratory failure.","authors":"Makenzie Hamilton, Marybeth Burriss-West, Desiree Bonadonna, Caroline P Ozment, Kyle J Rehder","doi":"10.1080/17476348.2025.2536887","DOIUrl":"10.1080/17476348.2025.2536887","url":null,"abstract":"Introduction: Extracorporeal membrane oxygenation (ECMO) remains a mainstay for refractory respiratory failure in select pediatric patients. Clinical practice surrounding its use continues to evolve, reflecting advances in technology, management strategies, and patient selection. Ongoing research and innovation are actively shaping VV-ECMO's future directions aimed at optimizing outcomes and increasing understanding of best practices.Areas covered: This review summarizes the fundamental concepts of VV-ECMO and highlights established practices and ongoing questions with a focus on indications/contraindications, cannulation, ventilator management, anticoagulation, fluid management, and weaning/decannulation. We also examine recent advancements and emerging technologies that are shaping the evolution of pediatric ECMO therapy. Narrative literature review of the PubMed central database was utilized to help inform this review.Expert opinion: Despite recent progress in pediatric VV-ECMO, substantial gaps remain in understanding optimal practices. And while there are many promising advances, there is a need for high-quality, collaborative research to further define best practices and guide ongoing future improvements for this life-sustaining therapy.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1233-1245"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging role of hyperpolarized ¹²⁹Xe MRI in pulmonary hypertension. 超极化129Xe MRI在肺动脉高压中的新作用。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-07-10 DOI: 10.1080/17476348.2025.2529543

Fawaz Alenezi, Anna Costelle, Seth Lee, Bastiaan Driehuys, Sudarshan Rajagopal

引用次数: 0

Addressing advance care planning for idiopathic pulmonary fibrosis: a call to action. 解决特发性肺纤维化的预先护理计划：行动呼吁。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-12-01 Epub Date: 2025-07-10 DOI: 10.1080/17476348.2025.2528947

Annlise Calypso, Sonye K Danoff, Rebecca Anna Gersten

{"title":"Addressing advance care planning for idiopathic pulmonary fibrosis: a call to action.","authors":"Annlise Calypso, Sonye K Danoff, Rebecca Anna Gersten","doi":"10.1080/17476348.2025.2528947","DOIUrl":"10.1080/17476348.2025.2528947","url":null,"abstract":"Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by relentless parenchymal scarring, deteriorating pulmonary function, and unpredictable exacerbations. The prognosis remains poor, despite antifibrotic and other therapies. Patients with IPF experience a high symptom burden, frequent hospitalizations, and uncertainty regarding disease progression. Advance care planning (ACP), the process of defining patients' preferences for medical care, is inconsistently implemented in IPF care. This often leads to end-of-life care unaligned with the patient's wishes and increased distress amongst patients and their care partners.Areas covered: In this perspective, we argue for the early and routine integration of ACP into IPF management. We review the multifaceted patient-, provider-, and system-level barriers to ACP and propose actionable strategies to normalize, document, and operationalize patient-centered ACP across the IPF disease trajectory. We highlight the critical need for an interdisciplinary team to best address ACP.Expert opinion: While IPF research has resulted in huge progress in the understanding of disease pathobiology and the expansion of treatment options, perhaps the most patient-centered portion of care remains under-studied. We must prioritize research to better understand an interdisciplinary system of iterative ACP that gives IPF patients a clear voice until the last moment of life.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1171-1179"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0